Is the price fair?
What AMRX's price assumes
Amneal Pharmaceuticals, Inc. trades at 44.9× earnings against 24.3× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
44.9
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.3 · 1.85× the median: the market pays up for this one
- Price / sales
- 1.34
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.4%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.4%
- Growth the price implies
- +7.5%
Growth the price implies · The price pays for +7.5% free cash flow growth a year for a decade; the business has delivered +83% a year over the last three.
Details›
- EV / EBIT2026-Q1
- 14.8
- EV / sales2026-Q1
- 2.12
- Healthcare median P/E362 names
- 29.9
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.3
- Free cash flow, trailing twelve months
- $241M
- Market capitalisation
- $5.53B
- 3-year revenue growth
- +10%
- 3-year free cash flow growth
- +83%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #22 of 29 by Smart Score